Salipro® unlocks Structural Insights into Key Metabolic Transporter SLC33A1

Great science enabled by Salipro®: A new study published in Cell Discovery, details the cryo-EM structure of the human acetyl-CoA transporter SLC33A1, offering mechanistic insights crucial for targeting diseases like neurodegeneration and cancer.

Understanding how SLC33A1 recognizes and transports its substrate is vital for developing novel therapeutics. With the Salipro® platform, the authors successfully stabilized human SLC33A1, enabling researchers to determine its 3.5 Å cryo-EM structure complexed with acetyl-CoA.

Key implications of this research:

• Advances fundamental understanding of SLC33A1's vital physiological functions.

• Provides a structural blueprint with significant potential to guide drug development for conditions including neurodegenerative disorders, aging-related diseases, and certain cancers.

SLC transporters represent a significant class of drug targets, and this work showcases how the Salipro® platform makes challenging targets like SLCs, GPCRs, and ion channels accessible for next-generation therapeutic development.

Read the full article here: D. Zhou, et al., Mechanistic insights into the acetyl-CoA recognition by SLC33A1. Cell Discov. 11, 36 (2025).